How Oral Mucosa Absorption Works: Anatomy and Limits

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Sublingual and buccal mucosa can absorb part of a dose in contact with them. The absorbed fraction bypasses initial hepatic first-pass exposure; the swallowed remainder follows the gastrointestinal route. Sublingual tissue runs about 100 to 200 micrometers thick, versus 500 to 800 micrometers buccal. Passive absorption favors smaller molecules with suitable lipophilicity, solubility, and ionization; a model based on porcine buccal data puts the polar pathway's pore radius at 1.5 to 3 nanometers. Total surface area is roughly 100 to 200 square centimeters; a fraction contacts any one oral dissolving strip (ODS). MIHIYO Labs uses these constraints to guide dose and contact-time targets, not as evidence of measured product absorption.

How Does the Oral Mucosa Absorb an Active Compound?

A film placed under the tongue or against the cheek does not need to be swallowed for part of its dose to reach the bloodstream directly. The fraction that stays in contact long enough to cross needs a patch of tissue thin enough, and vascular enough, for the active ingredient to reach local capillaries; whatever gets swallowed instead follows the ordinary gastrointestinal route. That patch of tissue is the oral mucosa: the lining of the mouth, made of a stratified epithelium sitting over a dense capillary bed, with venous drainage that reaches the systemic circulation without first passing through the hepatic portal system.⁵

My doctoral research is in transmucosal drug delivery and oral thin-film design, and the question I keep returning to is not "does the oral mucosa absorb drugs" — it does, and has for decades, going back to the long-established use of sublingual nitroglycerin¹ — but which molecules it absorbs well, through which part of the mouth, and how long a film actually needs to sit there before that matters. Those are anatomy and physical-chemistry questions, not marketing questions, and the answers put hard limits on what any oral film, including ours, can be formulated to do.

What Makes Sublingual and Buccal Tissue Different From Skin or Gut Lining?

The mouth is not one uniform surface. The gums and hard palate are covered in keratinized epithelium — the same tough, cornified cell type that makes skin an effective barrier — built to withstand chewing.² The tissue under the tongue and against the inner cheek is different: non-keratinized, thinner, and more flexible, which is also why it is generally more permeable than the keratinized gingiva and hard palate.²⁶

That thinness is measurable and it varies by site. Sublingual epithelium runs about 100 to 200 micrometers thick across roughly 8 to 12 cell layers; buccal epithelium is thicker, about 500 to 800 micrometers across 40 to 50 cell layers.¹⁴ Both are covered by a mucus layer with an average thickness of roughly 70 to 100 micrometers.⁴ Sublingual tissue's relative thinness is generally described as giving it more direct access to the systemic circulation, while the buccal site's larger surface area makes it a common choice for mucoadhesive films designed to stay in place longer.¹

The principal permeability barrier sits within the superficial epithelial layers, shaped by the composition and organization of intercellular lipids, not cell count alone.⁶ In keratinized tissue, membrane-coating granules pack the upper cell layers with ceramides and other neutral lipids that seal the surface; non-keratinized tissue instead carries more polar intercellular lipids, arranged less densely — one reason it is generally more permeable, not simply a matter of being thinner.⁶ For the lipid-mediated route, passive permeability favors smaller molecules with a suitable balance of lipophilicity, solubility, and ionization at oral pH; molecular weight itself showed only a modest effect once lipophilicity was accounted for. Polar permeants and macromolecules, instead, are commonly modeled as crossing predominantly through a polar, likely paracellular pathway with a much steeper size dependence. Hindered-transport analysis of that pathway, based mainly on ex vivo porcine buccal data, estimated an effective pore radius of roughly 1.5 to 3 nanometers — a model-derived figure, not one measured directly by microscopy or separately established for sublingual or human buccal tissue.³ That steep size dependence helps explain why most peptides and proteins show poor passive buccal permeability without a permeation enhancer or different delivery route.³

Once a molecule crosses, where that fraction goes next matters as much as how it got through. Sublingual and buccal capillaries drain into the deep lingual and facial veins, leading to the superior vena cava and the heart, rather than entering the portal circulation first, as most gastrointestinally absorbed compounds do.⁵ Oral mucosal tissue is also less enzymatically active than the gut wall and liver, which can lower degradation risk for actives, including peptides, before absorption completes — though that alone does not solve the permeability problem: most peptides still cross the mucosa poorly and generally need a specialized carrier or permeation-enhancing strategy to reach a useful concentration.⁵ Neither fact means every absorbed molecule fully escapes metabolism — the mouth is not metabolically inert — but the combination of a shorter enzymatic gauntlet and a venous route that skips the liver's first pass is the physiological reason this class of delivery exists at all.

How Much Surface Area Does the Oral Mucosa Actually Offer?

None of this happens over a large surface. The entire oral cavity offers only roughly 100 to 200 square centimeters of mucosal surface area combined, across the buccal, sublingual, gingival, palatal, and labial regions — and only a fraction of that area is ever in contact with a single film.⁴⁵ Of that total, the sublingual region contributes an estimated 26.5 square centimeters and the buccal region about 50.2 square centimeters — a small fraction of the body's other absorptive surfaces, such as the intestine.⁴

That small surface area is a real design constraint, not a footnote. It caps how much active ingredient can realistically be delivered by passive mucosal absorption alone, favoring low-dose actives with favorable permeability over the gram-scale doses some swallowed supplements carry; based on computed physicochemical properties, melatonin is a more plausible candidate on paper than 5-HTP.⁹ If a film contains more active than can plausibly cross the available mucosal area during its residence time, a larger fraction of the dose is likely to be swallowed and absorbed through the gastrointestinal route instead.

What This Means for MIHIYO's Formulation Choices

Every MIHIYO strip is designed around the same question my doctoral work keeps circling back to: given this molecule's size and physicochemical properties, and this tissue's thickness and dwell time, how much of a dose has a realistic chance to cross before the rest is swallowed? 5-HTP, the active in the Mood-Boost ODS, is a relatively polar, hydrophilic molecule by published computed data — molecular weight about 220, XLogP about −1.2, topological polar surface area about 99 Ų.⁹ These properties suggest passive mucosal permeability may be limited, but do not substitute for direct testing: 5-HTP also contains ionizable amino and carboxyl groups, so XLogP alone cannot fully predict its behavior at oral pH; a pH-specific distribution coefficient would better characterize its partitioning, though direct permeation testing would still be required. Melatonin, by contrast, has a lower polar surface area and a positive XLogP — properties more consistent with passive mucosal crossing on paper, though our finished Sleep-Support strip has not been tested either.⁹ I formulate 5-HTP into a strip for its fixed, low, premeasured unit dose, not as a claim that it delivers a meaningful transmucosal fraction: a 2023 compatibility study formulated 50 mg of 5-HTP into an orodispersible film, measured a 46.2-second in vitro disintegration time, and used HPLC content-recovery testing to support a 150-day beyond-use date at room temperature — but did not measure mucosal permeation or human pharmacokinetics.⁸ Establishing an actual transmucosal contribution would require product-specific studies designed to distinguish mucosal absorption from the swallowed fraction.

The trade-off I keep coming back to in the lab is dwell time versus mouthfeel. A film that dissolves within a few seconds may leave little time for transmucosal contact before most of the dissolved dose is swallowed. A longer residence time may allow more absorption, but only if the active is sufficiently permeable to begin with. MIHIYO uses a 30-to-60-second disintegration target as an internal formulation goal to balance contact time against mouthfeel — the film must hold together on the tongue without turning gummy or unpleasant, a polymer and plasticizer problem as much as a pharmacology one. Whether that window produces a meaningfully larger transmucosal fraction than a shorter one depends on the active's own permeability and requires product-specific testing; the anatomy literature supports sublingual tissue generally favoring faster access, not a validated threshold for every active.

None of this is a claim that MIHIYO's finished strips have been tested for systemic bioavailability, or that the specific contribution of transmucosal absorption has been established in a human pharmacokinetic study — neither has been done. The anatomy and permeability data above come from general mucosal-tissue and cell-model research, not from a study run on a MIHIYO product. What that research does is discipline the formulation: it tells me which doses and which molecules are physically plausible candidates for this route, and which ones are better served swallowed. I write more about how the liver step specifically changes a dose's fate once it is swallowed in a separate article on the first-pass effect, and about how bioavailability is measured and reported in a companion piece on what bioavailability actually means.

Where Oral-Mucosal Absorption Falls Short

The oral cavity is not a passive dish. Saliva is constantly produced and swallowed, and that turnover, together with swallowing itself, helps limit how long any dissolved dose stays in contact with absorptive tissue and makes prolonged unprotected contact difficult. In one study of 159 healthy adults, median unstimulated whole-saliva flow was 0.48 milliliters per minute, with an observed range of 0.1 to 2 milliliters per minute across that cohort; the study estimated the lower limit of normal, using a fifth-percentile cutoff, at 0.15 milliliters per minute.⁷ A formulation that assumes indefinite mucosal contact is assuming away one of the biggest physiological variables in the room.

Molecular size and polarity set a harder ceiling. The buccal paracellular route's modeled 1.5-to-3-nanometer effective pore radius — estimated mainly from porcine tissue data — helps explain why most peptides, proteins, and other large or highly polar actives show poor passive absorption without a permeation enhancer, which introduces its own formulation and safety questions.³ Charge, ionization state, and enzymatic stability matter too — molecular size alone does not decide whether a given active is a workable candidate — but together these factors make many supplement actives poor candidates for passive transmucosal delivery in a conventional film, unless specialized carriers or carefully validated permeation-enhancing strategies are used.

The limited surface area compounds both problems. With only roughly 100 to 200 square centimeters of oral mucosa in total, and a fraction of that in useful contact with any given film, surface area contributes to a practical ceiling on the dose that can cross during the available time. Meaningful systemic transmucosal delivery is therefore generally most practical for potent, relatively low-dose actives with suitable permeability characteristics, and the fit still depends on that molecule's own permeability, not dose size alone.⁴ Individual variability — saliva flow, placement habit, how quickly someone swallows — means the same film will not perform identically in every mouth. Sublingual and buccal absorption is real and mechanistically grounded. It is not a universal upgrade over swallowing, and it does not suit every ingredient a label might want on a strip.

The Bottom Line

Oral mucosa absorption works, for the fraction of a dose in contact long enough to cross, because the tissue under the tongue and cheek is thin, non-keratinized, and drains through veins that bypass the liver's first-pass step — not because "sublingual" is inherently a stronger word than "oral." The advantage is real but bounded: a roughly 100-to-800-micrometer-thick barrier, a modeled buccal pore size in the low nanometers, roughly 100 to 200 square centimeters of surface area, and a saliva flow that continuously limits contact time. Those numbers, not marketing language, determine whether a molecule is a plausible candidate for meaningful transmucosal delivery — not whether it can be formulated into a dissolving film for other reasons, such as dose precision or portability. At MIHIYO Labs, I use them as design constraints for every strip we build, and as limits on what any oral dissolving strip can responsibly claim without product-specific testing.

References

1. Bahraminejad S, Almoazen H. Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive. Pharmaceutics. 2025;17(8):1073. PMID: 40871092. DOI: 10.3390/pharmaceutics17081073. https://pmc.ncbi.nlm.nih.gov/articles/PMC12389210/
2. Squier CA, Kremer MJ. Biology of Oral Mucosa and Esophagus. Journal of the National Cancer Institute Monographs. 2001;(29):7-15. PMID: 11694559. DOI: 10.1093/oxfordjournals.jncimonographs.a003443. https://pubmed.ncbi.nlm.nih.gov/11694559/
3. Wanasathop A, Patel PB, Choi HA, Li SK. Permeability of Buccal Mucosa. Pharmaceutics. 2021;13(11):1814. PMID: 34834229. DOI: 10.3390/pharmaceutics13111814. https://pmc.ncbi.nlm.nih.gov/articles/PMC8624797/
4. Hua S. Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration. Frontiers in Pharmacology. 2019;10:1328. PMID: 31827435. DOI: 10.3389/fphar.2019.01328. https://pmc.ncbi.nlm.nih.gov/articles/PMC6848967/
5. Špiljak B, Somogyi Škoc M, Rezić Meštrović I, Bašić K, Bando I, Šutej I. Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans. Pharmaceutics. 2025;17(9):1212. PMID: 41012547. DOI: 10.3390/pharmaceutics17091212. https://pmc.ncbi.nlm.nih.gov/articles/PMC12473735/
6. Squier CA. The Permeability of Oral Mucosa. Critical Reviews in Oral Biology & Medicine. 1991;2(1):13-32. PMID: 1912142. DOI: 10.1177/10454411910020010301. https://pubmed.ncbi.nlm.nih.gov/1912142/
7. Fenoll-Palomares C, Muñoz Montagud JV, Sanchiz V, Herreros B, Hernández V, Mínguez M, Benages A. Unstimulated Salivary Flow Rate, pH and Buffer Capacity of Saliva in Healthy Volunteers. Revista Española de Enfermedades Digestivas. 2004;96(11):773-783. PMID: 15584851. DOI: 10.4321/s1130-01082004001100005. https://pubmed.ncbi.nlm.nih.gov/15584851/
8. Polonini HC, Ferreira AO, Raposo NRB, da Silva PJLC, Brandão MAF. Compatibility Assessment of Novel Orodispersible Film Vehicle for Personalized Medicine with Selected Active Pharmaceutical Ingredients. Journal of Personalized Medicine. 2023;13(11):1565. PMID: 38003880. DOI: 10.3390/jpm13111565. https://pmc.ncbi.nlm.nih.gov/articles/PMC10672364/
9. National Center for Biotechnology Information. PubChem Compound Summary for CID 439280, Oxitriptan (L-5-Hydroxytryptophan); and CID 896, Melatonin. PubChem Database. Computed properties (molecular weight, XLogP3, topological polar surface area). Accessed August 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/439280 ; https://pubchem.ncbi.nlm.nih.gov/compound/896

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.